David Hochman Acquires 5,000 Shares of Orchestra BioMed (NASDAQ:OBIO) Stock

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) insider David Hochman bought 5,000 shares of Orchestra BioMed stock in a transaction on Monday, June 1st. The shares were purchased at an average price of $3.83 per share, for a total transaction of $19,150.00. Following the acquisition, the insider directly owned 1,064,029 shares in the company, valued at approximately $4,075,231.07. This trade represents a 0.47% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Orchestra BioMed Stock Down 1.3%

OBIO stock opened at $3.86 on Thursday. Orchestra BioMed Holdings, Inc. has a fifty-two week low of $2.20 and a fifty-two week high of $5.42. The business’s 50 day moving average price is $4.14 and its two-hundred day moving average price is $4.27. The company has a debt-to-equity ratio of 0.35, a quick ratio of 7.01 and a current ratio of 7.03. The company has a market capitalization of $231.14 million, a price-to-earnings ratio of -3.98 and a beta of 0.50.

Orchestra BioMed (NASDAQ:OBIO) last posted its earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.07. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%.The firm had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.92 million. As a group, analysts forecast that Orchestra BioMed Holdings, Inc. will post -1.47 earnings per share for the current fiscal year.

Institutional Trading of Orchestra BioMed

Institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. purchased a new stake in Orchestra BioMed during the 4th quarter valued at $38,000. Creative Planning purchased a new stake in Orchestra BioMed during the 2nd quarter valued at $40,000. XTX Topco Ltd purchased a new stake in Orchestra BioMed during the 2nd quarter valued at $45,000. Jane Street Group LLC purchased a new stake in Orchestra BioMed during the 2nd quarter valued at $50,000. Finally, Virtu Financial LLC purchased a new stake in Orchestra BioMed during the 4th quarter valued at $57,000. 53.20% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Barclays upped their price target on Orchestra BioMed from $12.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Wall Street Zen downgraded Orchestra BioMed from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Chardan Capital restated a “buy” rating and issued a $20.00 price target on shares of Orchestra BioMed in a research note on Thursday, March 12th. B. Riley Financial cut their price target on Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Orchestra BioMed in a research note on Thursday, May 14th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $13.60.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical?stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high?unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early? and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.